Fromkin Andrew J. reported option exercise involving 31,668 shares of Immunovant, Inc. at $4.99 for $158k on May 28, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$158,023.32Shares × reported price
Shares traded
31,668Common Stock
Price per share
$4.99Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
131,400Direct
Trade date
May 28, 2026Option exercise
Filed
May 29, 2026, 4:04 PM ET1-day reporting delay
Accession
0001341896-26-000004Code M · Transaction 94185
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

IMVT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMVT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago +2.5%1d ago +0.3%
Returns since7d −6.5%30d +17%90d180d1y

Footnotes in full

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 - $33.035 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 - $33.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F3: Reflects an award of stock options to purchase Common Shares that is fully vested.